Get the Stockscreener App
1.145
2.97%
-0.035
Alector Inc stock is traded at $1.145, with a volume of 159.43K.
It is down -2.97% in the last 24 hours and down -11.24% over the past month.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
159.43K
Relative Volume:
0.24
Market Cap:
$91.17M
Revenue:
$100.56M
Net Income/Loss:
$-119.05M
P/E Ratio:
-0.9309
EPS:
-1.23
Net Cash Flow:
$-231.16M
1W Performance:
+24.44%
1M Performance:
-11.24%
6M Performance:
-75.95%
1Y Performance:
-76.20%
1-Day Range:
$1.135
$1.195
1-Week Range:
$0.904
$1.24
52-Week Range:
$0.87
$6.78
Alector Inc Stock (ALEC) Company Profile
Name
Alector Inc
Sector
Industry
Phone
415-231-5660
Address
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.15 | 91.17M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.32 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.41 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
606.47 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.13 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
246.73 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Downgrade | Mizuho | Outperform → Neutral |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-29-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-26-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-14-23 | Upgrade | Stifel | Hold → Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Sep-25-23 | Initiated | Goldman | Sell |
| Sep-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-13-22 | Initiated | Goldman | Sell |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Sep-27-21 | Initiated | William Blair | Outperform |
| Jan-15-21 | Resumed | BofA Securities | Buy |
| Jun-24-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Goldman | Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-19-20 | Initiated | Stifel | Buy |
| Nov-21-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | Barclays | Overweight |
| Mar-04-19 | Initiated | BofA/Merrill | Buy |
| Mar-04-19 | Initiated | Morgan Stanley | Overweight |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
View All
Alector Inc Stock (ALEC) Latest News
Following a 75% decline over last year, recent gains may please Alector, Inc. (NASDAQ:ALEC) institutional owners - simplywall.st
There is no way Alector Inc (ALEC) can keep these numbers up - Sete News
A Guide To The Risks Of Investing In Alector Inc (ALEC) - knoxdaily.com
ALEC’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Neogenomics Inc (NEO) Stock’s Detailed Analysis - Marketing Sentinel
Alector Inc (ALEC): What Makes The Stock Good? - Marketing Sentinel
Gentherm Inc Is A Buy Small Cap Stock: Analysts - Marketing Sentinel
Alector, Inc. (NASDAQ:ALEC) Holdings Cut by JPMorgan Chase & Co. - Defense World
Alector concludes enrolment in Phase II trial of Alzheimer’s treatment - Yahoo Finance
What Analysts Were Expecting After Alector Inc (NASDAQ: ALEC) fell -5.95% - Stocksregister
Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101 - marketscreener.com
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease - GlobeNewswire
Alector (ALEC) Completes Enrollment for Alzheimer's Drug Trial | ALEC Stock News - GuruFocus
Major Milestone: Alector's Innovative Alzheimer's Drug Trial Hits Full Enrollment Ahead of Schedule - Stock Titan
Alector stock hits 52-week low at $0.99 amid sharp decline By Investing.com - Investing.com South Africa
Alector stock hits 52-week low at $0.99 amid sharp decline - Investing.com India
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
Brokerages Set Alector, Inc. (NASDAQ:ALEC) Price Target at $3.50 - Defense World
Alector stock hits 52-week low at $1.24 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Reduces Stock Position in Alector, Inc. (NASDAQ:ALEC) - Defense World
Alector, Inc. (NASDAQ:ALEC) Shares Sold by Charles Schwab Investment Management Inc. - The AM Reporter
Alector Announces Resignation of Chief Medical Officer - TipRanks
Alector Appoints New Chief Medical Officer - MarketScreener
Alector Provides Executive Leadership Update - The Manila Times
Alector Names Neurology Expert as CMO Amid Crucial Phase 3 Dementia Trial - Stock Titan
Alector Cuts Staff Again, This Time Laying Off 13% of Workforce - BioSpace
Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Alector stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia
Alector at Virtual CNS Forum: Advancing Neurodegenerative Treatments By Investing.com - Investing.com South Africa
Alector at Virtual CNS Forum: Advancing Neurodegenerative Treatments - Investing.com
Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point (NASDAQ:ALEC) - Seeking Alpha
Mizuho’s latest rating for ALEC stock - Knox Daily
Alector at Leerink Global Healthcare Conference: Strategic Advances in Neurodegeneration - Investing.com India
Alector announces workforce reduction to cut costs By Investing.com - Investing.com Australia
Alector announces workforce reduction to cut costs - Investing.com
Alector to Cut 13% of Workforce - MarketWatch
Have Alector Insiders Been Selling Stock? - simplywall.st
Alector, Inc. (NASDAQ:ALEC) Receives $3.75 Consensus Target Price from Analysts - Defense World
Alector assumed with an Underweight at Morgan Stanley - TipRanks
Alector at TD Cowen Conference: Advancing Neurodegenerative Therapies - Investing.com India
Alector at TD Cowen Conference: Advancing Neurodegenerative Therapies By Investing.com - Investing.com UK
Alector Executives Sell Shares to Satisfy Tax Obligations - TradingView
Alector stock hits 52-week low at $1.54 amid sharp annual decline - Investing.com Australia
HC Wainwright Brokers Raise Earnings Estimates for Alector - The AM Reporter
Alector stock hits 52-week low at $1.54 amid sharp annual decline By Investing.com - Investing.com South Africa
Alector Inc Stock (ALEC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alector Inc Stock (ALEC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | Chief Executive Officer |
Mar 03 '25 |
Sale |
1.47 |
40,330 |
59,176 |
2,466,744 |
| GRASSO MARC | Chief Financial Officer |
Mar 03 '25 |
Sale |
1.47 |
18,091 |
26,547 |
312,560 |
| Romano Gary | Chief Medical Officer |
Mar 03 '25 |
Sale |
1.47 |
16,306 |
23,927 |
332,977 |
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):